Clinical Trials · NCT06131372
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 626
- Start date
- Apr 2024
- Locations
- 128 sites, 13 countries
- Primary endpoint
- Change in urinary albumin-to-creatinine ratio (UACR)